OmniAb to Report Fourth Quarter 2022 Financial Results on March 30

Rhea-AI Summary

OmniAb, Inc. (NASDAQ: OABI) will release its financial results for the three and 12 months ending December 31, 2022 on March 30, 2023, after market close. A conference call to discuss these results and business updates is scheduled for the same day at 4:30 p.m. Eastern time. Investors can join the call in the U.S. at (888) 886-7786 or internationally at +1 (416) 764-8658, using conference ID 43857264. A live and replay webcast will be available here.

Positive

• Scheduled financial results announcement indicating transparency and engagement with investors.

Negative

• None.

EMERYVILLE, Calif.--(BUSINESS WIRE)-- OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2022 after the close of the U.S. financial markets on Thursday, March 30, 2023 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

Conference Call and Webcast Information

What:		OmniAb conference call to discuss financial results and business updates
Date:		Thursday, March 30, 2023
Time:		4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Conference Call:		U.S. (888) 886-7786
		International +1 (416) 764-8658
		Conference ID is 43857264
Webcast:		Live and replay webcast of the call with slides will be available here.

About OmniAb^®

OmniAb, Inc.’s discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence™ (BI) of our proprietary transgenic animals, including OmniRat^®, OmniChicken^® and OmniMouse^® that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic^® (transgenic rat) and OmniClic^® (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur^™ features unique structural attributes of cow antibodies for complex targets. We believe the OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities in emerging target classes. OmniAb antibodies have been leveraged across modalities, including bispecific antibodies, antibody-drug conjugates and others. The OmniAb suite of technologies span from BI-powered repertoire generation to cutting edge antibody discovery and optimization offering a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry.

For more information, please visit www.omniab.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230309005080/en/

OmniAb, Inc.

investors@OmniAb.com

Twitter @OmniAbTech

(510) 250-7801

LHA Investor Relations

Yvonne Briggs

ybriggs@lhai.com

(310) 691-7100

Source: OmniAb, Inc.

FAQ

When will OmniAb report its financial results for 2022?

OmniAb will report its financial results for the three and 12 months ended December 31, 2022, on March 30, 2023.

What time is the OmniAb conference call scheduled for?

The OmniAb conference call is scheduled for 4:30 p.m. Eastern time on March 30, 2023.

How can I join the OmniAb conference call?

You can join the OmniAb conference call by calling (888) 886-7786 in the U.S. or +1 (416) 764-8658 internationally.

Is there a webcast for the OmniAb financial results call?

Yes, a live and replay webcast of the OmniAb financial results call will be available.